Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2020 13:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results

CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
February 26, 2020 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Present at Investor Conferences

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
January 06, 2020 12:33 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
December 13, 2019 16:05 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
December 10, 2019 21:05 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
December 09, 2019 16:18 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
December 09, 2019 10:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%)...
December 02, 2019 11:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610

CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
November 13, 2019 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
November 06, 2019 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results

First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right